Telix Pharmaceuticals

Trial and FDA signals

• FDA complete response letter Received an FDA complete response letter (BLA 761401, letter dated Apr 10, 2026). FDA BLA 761401 (Apr 10, 2026)
  Evidence (1 event)

  • Apr 10, 2026 · FDA BLA 761401
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Telix Pharmaceuticals (US) Inc. Attention: Yvonne Chow Global Regulatory Affairs Manager Fishers, IN (street omitted) Dear Yvonne Chow: We refer to your biologics li

Job counts as of Oct 18, 2026. All trial and FDA signals